Piramal Healthcare

Piramal Healthcare, India’s second largest pharmaceutical healthcare company that brought itself in the spotlight with the whopping $3.72 Piramal-Abbott deal last year in 2010 came into news once again today with yet another agreement.Run by billionaire Ajay Piramal, the country’s biggest drugmaker, Piramal Healthcare has picked up a 5.5 percent equity stake in Vodafone Essar, the Indian operations of the world's largest mobile operator Vodafone Plc.[caption id="attachment_59238" align="alignleft" width="380" caption="Ajay Piramal,chairman of Piramal Healthcare. Reuters"][/caption]In the Abbott deal, the pharmaceutical company was paid $400 million as deferred payments for four years, valuing the deal at 9.5 times the company's actual valuation along with Piramal's 350 brands and trademarks.

Piramal had big plans to utilise the funds it raised with the Abbott deal in the existing businesses and to explore new areas including non-pharama. The chairman of Piramal was quoted as saying, “We will build a good value to the remaining business.”

The Vodafone Essar deal sure did not come as a surprise, considering Piramal’s earlier plans. Vikas Dandekar, India bureau chief of Pharmasianews pointed out that the Piramal-Vodafone deal can be a smart move, considering the value accretion to be gathered over a long period of time and the possibility of  coming up with an IPO.Based in Mumbai, the healthcare company has a presence in the cardio-vascular segment, the antibiotics and respiratory segments, pain management, neuro-psychiatry and anti-diabetics segments and the biotechnology segment too. With a growth track record of above 29 percent CAGR since 1988, Piramal Healthcare Ltd is ranked 4th in the Indian market with a diverse product portfolio spanning several therapeutic areas. It also takes pride in being the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia.It has a growth track record of above 29 percent CAGR  (Compounded Annual Growth Rate)  since 1988. Piramal Healthcare had consolidated revenues of  $ 656 million in 2009.  PHL is currently ranked 4th in the Indian market with a diverse product portfolio spanning several therapeutic areas. It is also one of the largest custom manufacturing companies with a global footprint of assets across North America, Europe and Asia.